Skip to main content
. Author manuscript; available in PMC: 2009 May 13.
Published in final edited form as: Nature. 2008 Oct 5;456(7219):269–273. doi: 10.1038/nature07349

Figure 3. P300/CBP modulate hepatic CRTC2 activity.

Figure 3

a, Top, Ad-CRE-luc activity in 6 hour fasted mice expressing Ad-CBP RNAi, Ad-P300 RNAi, or Ad-USi. Bottom, G6Pase mRNA amounts (left) and blood glucose levels (right) in mice expressing Ad-P300 RNAi relative to control. (n=3; * P <.001; ** P <.01). b, Effect of P300/CBP HAT inhibitor Lys-CoA-TAT or control TAT peptide on CRTC2 acetylation (top) and Ad-CRE-luc activity (bottom) in primary hepatocytes exposed to glucagon. (n=3; P <.001). c, Effect of Lys-CoA-TAT on CRTC2 protein amounts (top) and on glucose output (bottom) from primary hepatocytes expressing wild-type or Lys628Arg mutant CRTC2 (n=3; P < .001). d, Top, Ad-CRE-luc activity in 6 hour fasted mice imaged prior to (Pre) or following (Post) IP injection of Lys-CoA-TAT or TAT peptide. Bottom, blood glucose concentrations in 8 hr. fasted mice injected with Lys-coA-TAT or TAT control. For blood glucose levels (n=6; P < .001). For panels a, b, c, d, data are means ± s.e.m.